Table 3.
Analysis of CTA expression by immunohistochemistry in different non-Hodgkin’s lymphoma subgroups (n = 106)
| Clinical data | N | 0 CTA ( %) | N | ≥1 CTA (%) | p value |
|---|---|---|---|---|---|
| NHL cell origin | |||||
| B-cell | 79 | 88.8 | 10 | 11.2 | 0.928 |
| T-cell | 14 | 87.5 | 2 | 12.5 | |
| Null | 1 | 100.0 | 0 | 0 | |
| NHL clinical behavior | |||||
| Indolent | 31 | 96.9 | 1 | 3.1 | 0.102 |
| Aggressive | 63 | 85.1 | 11 | 14.9 | |
| DLBCL/non-DLBCL | |||||
| Non-DLBCL | 47 | 94.0 | 3 | 6.0 | 0.130 |
| DLBCL | 47 | 83.9 | 9 | 16.1 | |
| Ann Arbor staging | |||||
| I or II | 33 | 80.5 | 8 | 19.5 | 0.046 |
| III or IV | 61 | 93.8 | 4 | 6.2 | |
| IPI | |||||
| 0 or 1 | 27 | 87.1 | 4 | 12.9 | 0.990 |
| 2 or 3 | 41 | 89.1 | 5 | 10.9 | |
| 4 or 5 | 17 | 89.5 | 2 | 10.5 | |
| Not available | 9 | 90.0 | 1 | 10.0 | |
| Response | |||||
| Complete response | 41 | 93.2 | 3 | 6.8 | 0.230 |
| Non-complete response | 51 | 85.0 | 9 | 15.0 | |
| Not available | 2 | 100 | 0 | 0 | |
IPI international prognostic index